Prohippur (sodium benzoate)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- sodium benzoate
- Company
- Lucane Pharma
- Status
- Application withdrawn
- Therapeutic area
- Urea Cycle Disorders, Inborn; Hyperglycinemia, Nonketotic
- Designations
- Orphan
- Application
- EMEA/H/C/004150
- ATC
- A16AX11
- Official record
- www.ema.europa.eu
Indication
Treatment of non ketotic hyperglycinemia, urea cycle disorders including carbamoyl-phosphate synthase-1 deficiency, ornithine transcarbamylase deficiency, citrullinaemia type 1, argininosuccinic aciduria, hyperargininaemia, n-acetylglutamate synthase deficiency, ornithine translocase deficiency and lysinuric protein intolerance.
Regulatory milestones
No milestones recorded in the last year.
Follow Prohippur
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.